Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI) | Zendy

Kevin R. Bainey | Zendy; Robert C. Welsh | Zendy; Stuart J. Connolly | Zendy; Tamara Marsden | Zendy; Jackie Bosch | Zendy; Keith A.A. Fox | Zendy; Philippe Gabríel Steg | Zendy; Dragoş Vinereanu | Zendy; Derek Connolly | Zendy; Scott D. Berkowitz | Zendy; JoAnne M. Foody | Zendy; Jeffrey L. Probstfield | Zendy; Kelley R. Branch | Zendy; Basil S. Lewis | Zendy; Rafael Díaz | Zendy; Eva Muehlhofer | Zendy; Petr Widimský | Zendy; Salim Yusuf | Zendy; John W. Eikelboom | Zendy; Deepak L. Bhatt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)

Author(s) -

Kevin R. Bainey,

Robert C. Welsh,

Stuart J. Connolly,

Tamara Marsden,

Jackie Bosch,

Keith A.A. Fox,

Philippe Gabríel Steg,

Dragoş Vinereanu,

Derek Connolly,

Scott D. Berkowitz,

JoAnne M. Foody,

Jeffrey L. Probstfield,

Kelley R. Branch,

Basil S. Lewis,

Rafael Díaz,

Eva Muehlhofer,

Petr Widimský,

Salim Yusuf,

John W. Eikelboom,

Deepak L. Bhatt

Publication year - 2020

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.119.044598

Subject(s) - medicine , conventional pci , percutaneous coronary intervention , mace , aspirin , myocardial infarction , rivaroxaban , cardiology , hazard ratio , acute coronary syndrome , stroke (engine) , warfarin , confidence interval , atrial fibrillation , mechanical engineering , engineering

The COMPASS trial (Cardiovascular Outcomes for People using Anticoagulation Strategies) demonstrated that dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily versus aspirin 100 mg once daily reduced the primary major adverse cardiovascular event (MACE) outcome of cardiovascular death, myocardial infarction, or stroke, as well as, mortality, in patients with chronic coronary syndromes or peripheral arterial disease. Whether this remains true in patients with a history of percutaneous coronary intervention (PCI) is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research